Magnetic Particle-ICG Lymph Node Mapping in Colorectal Cancer

• Status: Not yet recruiting
• Trial end date: 2026-08-31
• Target enrollment: 0
• Participant gender: All

Summary

Study to determine the feasibility of Sentinel Lymph Node (SLN) mapping using novel magnetic tracers (FerroTrace) and indocyanine green (ICG) for colorectal cancer; and to evaluate safety by assessing short term toxicity associated with colonoscopic peritumoral injection of novel magnetic nanoparticles (FerroTrace) and ICG for colorectal cancer.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: M.D. Anderson Cancer Center

Criteria

Inclusion criteria:

• Age 18 or older

• Willing to provide informed consent

• Biopsy proven colon or rectal cancer

• No distant metastases

Exclusion criteria:

• Serious medical comorbidities or other contraindications to surgery +/- adjuvant therapy as determined by the treatment team

• Previous pelvic radiotherapy or radiotherapy planned prior to surgery

• Allergy or intolerance to iron oxide compounds

• Iron overload disorder

• Allergy or intolerance to iodides

• Pregnant or lactating women*